These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 31587290)

  • 1. Glial pathology in a novel spontaneous mutant mouse of the Eif2b5 gene: a vanishing white matter disease model.
    Terumitsu-Tsujita M; Kitaura H; Miura I; Kiyama Y; Goto F; Muraki Y; Ominato S; Hara N; Simankova A; Bizen N; Kashiwagi K; Ito T; Toyoshima Y; Kakita A; Manabe T; Wakana S; Takebayashi H; Igarashi H
    J Neurochem; 2020 Jul; 154(1):25-40. PubMed ID: 31587290
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Eif2b3 mutants recapitulate phenotypes of vanishing white matter disease and validate novel disease alleles in zebrafish.
    Lee YR; Kim SH; Ben-Mahmoud A; Kim OH; Choi TI; Lee KH; Ku B; Eum J; Kee Y; Lee S; Cha J; Won D; Lee ST; Choi JR; Lee JS; Kim HD; Kim HG; Bonkowsky JL; Kang HC; Kim CH
    Hum Mol Genet; 2021 Apr; 30(5):331-342. PubMed ID: 33517449
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Eukaryotic translation initiation factor 2B and leukoencephalopathy with vanishing white matter].
    Pan YX; Wu Y; Niu ZP; Jiang YW
    Beijing Da Xue Xue Bao Yi Xue Ban; 2009 Oct; 41(5):608-10. PubMed ID: 19829687
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Japanese girl with an early-infantile onset vanishing white matter disease resembling Cree leukoencephalopathy.
    Takano K; Tsuyusaki Y; Sato M; Takagi M; Anzai R; Okuda M; Iai M; Yamashita S; Okabe T; Aida N; Tsurusaki Y; Saitsu H; Matsumoto N; Osaka H
    Brain Dev; 2015 Jun; 37(6):638-42. PubMed ID: 25457085
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vanishing white matter disease expression of truncated EIF2B5 activates induced stress response.
    Keefe MD; Soderholm HE; Shih HY; Stevenson TJ; Glaittli KA; Bowles DM; Scholl E; Colby S; Merchant S; Hsu EW; Bonkowsky JL
    Elife; 2020 Dec; 9():. PubMed ID: 33300869
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Proteomics-level analysis of myelin formation and regeneration in a mouse model for Vanishing White Matter disease.
    Gat-Viks I; Geiger T; Barbi M; Raini G; Elroy-Stein O
    J Neurochem; 2015 Aug; 134(3):513-26. PubMed ID: 25920008
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vanishing white matter: deregulated integrated stress response as therapy target.
    Abbink TEM; Wisse LE; Jaku E; Thiecke MJ; Voltolini-González D; Fritsen H; Bobeldijk S; Ter Braak TJ; Polder E; Postma NL; Bugiani M; Struijs EA; Verheijen M; Straat N; van der Sluis S; Thomas AAM; Molenaar D; van der Knaap MS
    Ann Clin Transl Neurol; 2019 Aug; 6(8):1407-1422. PubMed ID: 31402619
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Energy Status of Astrocytes Is the Achilles' Heel of eIF2B-Leukodystrophy.
    Herrero M; Daw M; Atzmon A; Elroy-Stein O
    Cells; 2021 Jul; 10(8):. PubMed ID: 34440627
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of ten novel mutations in patients with eIF2B-related disorders.
    Ohlenbusch A; Henneke M; Brockmann K; Goerg M; Hanefeld F; Kohlschütter A; Gärtner J
    Hum Mutat; 2005 Apr; 25(4):411. PubMed ID: 15776425
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of novel EIF2B mutations in Chinese patients with vanishing white matter disease.
    Wu Y; Pan Y; Du L; Wang J; Gu Q; Gao Z; Li J; Leng X; Qin J; Wu X; Jiang Y
    J Hum Genet; 2009 Feb; 54(2):74-7. PubMed ID: 19158808
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of safety and early efficacy of AAV gene therapy in mouse models of vanishing white matter disease.
    Herstine JA; Chang PK; Chornyy S; Stevenson TJ; Sunshine AC; Nokhrina K; Rediger J; Wentz J; Vetter TA; Scholl E; Holaway C; Pyne NK; Bratasz A; Yeoh S; Flanigan KM; Bonkowsky JL; Bradbury AM
    Mol Ther; 2024 Jun; 32(6):1701-1720. PubMed ID: 38549375
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bergmann glia translocation: a new disease marker for vanishing white matter identifies therapeutic effects of Guanabenz treatment.
    Dooves S; Bugiani M; Wisse LE; Abbink TEM; van der Knaap MS; Heine VM
    Neuropathol Appl Neurobiol; 2018 Jun; 44(4):391-403. PubMed ID: 28953319
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ovarioleukodystrophy due to EIF2B5 mutations.
    Ibitoye RT; Renowden SA; Faulkner HJ; Scolding NJ; Rice CM
    Pract Neurol; 2016 Dec; 16(6):496-499. PubMed ID: 27651498
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Astrocytes are central in the pathomechanisms of vanishing white matter.
    Dooves S; Bugiani M; Postma NL; Polder E; Land N; Horan ST; van Deijk AL; van de Kreeke A; Jacobs G; Vuong C; Klooster J; Kamermans M; Wortel J; Loos M; Wisse LE; Scheper GC; Abbink TE; Heine VM; van der Knaap MS
    J Clin Invest; 2016 Apr; 126(4):1512-24. PubMed ID: 26974157
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Leukoencephalopathy with vanishing white matter: a review.
    Bugiani M; Boor I; Powers JM; Scheper GC; van der Knaap MS
    J Neuropathol Exp Neurol; 2010 Oct; 69(10):987-96. PubMed ID: 20838246
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biochemical effects of mutations in the gene encoding the alpha subunit of eukaryotic initiation factor (eIF) 2B associated with Vanishing White Matter disease.
    Wortham NC; Proud CG
    BMC Med Genet; 2015 Aug; 16():64. PubMed ID: 26285592
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mutations in the genes encoding eukaryotic translation initiation factor 2B in Japanese patients with vanishing white matter disease.
    Shimada S; Shimojima K; Sangu N; Hoshino A; Hachiya Y; Ohto T; Hashi Y; Nishida K; Mitani M; Kinjo S; Tsurusaki Y; Matsumoto N; Morimoto M; Yamamoto T
    Brain Dev; 2015 Nov; 37(10):960-6. PubMed ID: 25843247
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of a Missense Variant in the EIF2B3 Gene Causing Vanishing White Matter Disease with Antenatal-Onset but Mild Symptoms and Long-Term Survival.
    Khorrami M; Khorram E; Yaghini O; Rezaei M; Hejazifar A; Iravani O; Yazdani V; Riahinezhad M; Kheirollahi M
    J Mol Neurosci; 2021 Nov; 71(11):2405-2414. PubMed ID: 33687620
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A point mutation in translation initiation factor eIF2B leads to function--and time-specific changes in brain gene expression.
    Marom L; Ulitsky I; Cabilly Y; Shamir R; Elroy-Stein O
    PLoS One; 2011; 6(10):e26992. PubMed ID: 22073122
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The spectrum of mutations for the diagnosis of vanishing white matter disease.
    Scali O; Di Perri C; Federico A
    Neurol Sci; 2006 Sep; 27(4):271-7. PubMed ID: 16998732
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.